Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

George J Weiner

Showing results (1-10 of 117) with videos related to

Pageof 12
Sort By:
Immunologic Research|October 6, 2007
Monoclonal antibody mechanisms of action in cancerGeorge J Weiner
Advanced Drug Delivery Reviews|January 27, 2009
CpG oligodeoxynucleotide-based therapy of lymphoid malignanciesGeorge J Weiner
Blood|June 26, 2010
Making a better antibody: all is not lostGeorge J Weiner
Seminars in Hematology|March 31, 2010
Rituximab: mechanism of actionGeorge J Weiner
Nature Reviews. Cancer|May 23, 2015
Building better monoclonal antibody-based therapeuticsGeorge J Weiner
Cancer Biology & Therapy|May 22, 2004
Cancer biology--lost in translation?George J Weiner
Transactions of the American Clinical and Climatological Association|September 3, 2015
Anti-Lymphoma Monoclonal Antibodies: Making Better Antibodies and Making Antibodies BetterGeorge J Weiner
Journal of Leukocyte Biology|February 22, 2021
Immune checkpoint markers and anti-CD20-mediated NK cell activationZhaoming Wang, George J Weiner
Cancers|October 17, 2020
Quantification of Receptor Occupancy by Ligand-An Understudied Class of Potential BiomarkersSuresh Veeramani, George J Weiner
Current Opinion in Investigational Drugs (London, England : 2000)|August 7, 2003
CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapyBernd Jahrsdörfer, George J Weiner
Pageof 12

Showing results (1-10 of 117) with videos related to

Sort By:
Pageof 12
Immunologic Research|October 6, 2007
Monoclonal antibody mechanisms of action in cancerGeorge J Weiner
Advanced Drug Delivery Reviews|January 27, 2009
CpG oligodeoxynucleotide-based therapy of lymphoid malignanciesGeorge J Weiner
Blood|June 26, 2010
Making a better antibody: all is not lostGeorge J Weiner
Seminars in Hematology|March 31, 2010
Rituximab: mechanism of actionGeorge J Weiner
Nature Reviews. Cancer|May 23, 2015
Building better monoclonal antibody-based therapeuticsGeorge J Weiner
Cancer Biology & Therapy|May 22, 2004
Cancer biology--lost in translation?George J Weiner
Transactions of the American Clinical and Climatological Association|September 3, 2015
Anti-Lymphoma Monoclonal Antibodies: Making Better Antibodies and Making Antibodies BetterGeorge J Weiner
Journal of Leukocyte Biology|February 22, 2021
Immune checkpoint markers and anti-CD20-mediated NK cell activationZhaoming Wang, George J Weiner
Cancers|October 17, 2020
Quantification of Receptor Occupancy by Ligand-An Understudied Class of Potential BiomarkersSuresh Veeramani, George J Weiner
Current Opinion in Investigational Drugs (London, England : 2000)|August 7, 2003
CpG oligodeoxynucleotides for immune stimulation in cancer immunotherapyBernd Jahrsdörfer, George J Weiner
Pageof 12